[Lipoprotein regulatory effect of molsodomine in rats]

The antianginal drug N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine, Corvation) was orally administered (dose range 10(-5) - 10 mg/kg) to Wistar rats over 7 d once a day. The concentration of low density lipoprotein (LDL)-cholesterol in serum was decreased (40-45%) by therapeutic relevant dosages of molsidomine corresponding to an increase (80%) of the vasoprotective index high density lipoprotein (HDL)/LDL. HDL-cholesterol stayed unchanged. Clofibrate did not change the concentration of the lipoproteins in rat serum under equimolar conditions.